PCM
IRLA

Prelude Capital Management’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Prelude Capital Management’s Portfolio IRLA Stock Details IRLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-51
Closed -$14K – 1560
2022
Q3 		$14K Buy
+51
New +$19.4K ﹤0.01% 1291

Other funds holding IRLA

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Prelude Capital Management's IRLA Position: Q4 2022 in Review

Prelude Capital Management sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q4 2022, closing a stake of 51 shares — an estimated $14K sold.

Prelude Capital Management first reported a position in IRLA in Q3 2022 and held it in 1 quarter. The position peaked at $14K in Q3 2022. 48 funds tracked by Wall St. Rank hold IRLA as of Q4 2022.

  • Prelude Capital Management reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Prelude Capital Management sold 51 IRulya Therapeutics Inc. Common Stock shares in Q4 2022, an estimated $14K.
  • Prelude Capital Management first reported a position in IRulya Therapeutics Inc. Common Stock in Q3 2022 and held it in 1 quarter.
  • Prelude Capital Management's IRulya Therapeutics Inc. Common Stock position peaked at $14K in Q3 2022.
  • 48 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q4 2022.

Based on Prelude Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.